Hyder Jinnah, MD
Neurology · Atlanta, GANPI 1477500635
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Ipsen Innovation at 49.2% of the total. Among neurology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $1046.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Innovation$25K
- AbbVie$9K
- Merz Pharmaceuticals, LLC$7K
- Ipsen Pharma SAS$4K
- Travere Therapeutics, Inc.$2K
- Daiichi Sankyo Inc.$2K
- plus $2K from 4 others
Across 90 payments — averaging $6734.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$258K
- AbbVie$168K
- Ipsen Innovation$113K
- Travere Therapeutics, Inc.$60K
- Jazz Pharmaceuticals Inc.$7K
What the payments were for
- Consulting fees$26,07152%
- Speaking & faculty fees$16,76533%
- Travel & lodging$5,62111%
- Food & beverage$1,7774%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Innovation | 12 | $24,706 |
| AbbVie | 11 | $8,864 |
| Merz Pharmaceuticals, LLC | 9 | $7,368 |
| Ipsen Pharma SAS | 1 | $3,905 |
| Travere Therapeutics, Inc. | 4 | $2,050 |
| Daiichi Sankyo Inc. | 1 | $1,700 |
| Sage Therapeutics, LLC | 5 | $1,378 |
| Revance Therapeutics, Inc. | 2 | $210 |
| GE HealthCare | 2 | $40 |
| Merz North America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,234 in reported general payments places this provider in the 90th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 16 | $800 |
| Clonazepam | 36 | $219 |
Paid to pharmacies, not to this prescriber.
Other neurology in Atlanta
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Robert GilbertAtlanta$412K
- Lawrence SeidenAtlanta$272K
- Jacqueline RosenthalAtlanta$241K
- Ben ThrowerAtlanta$203K
- Jaime Hatcher MartinAtlanta$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.